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Abstract
Recently wild-type p53-induced phosphatase was implicated in the pathogen-
esis of acute myeloid leukemia (AML) and “pre-leukemia” myeloproliferative 
conditions. Here we decided to check how the strategy directed to phosphatase 
inhibition affected sensitivity to conventional chemotherapy. All experiments 
were conducted on AML cell lines cultivated in vitro. The levels of wild-type 
p53-induced phosphatase vary in different AML cell lines. The chemical com-
pound GSK2830371  reduced levels of phosphatase and diminished its activ-
ity. GSK2830371 did not significantly change the cell cycle distribution of AML 
cells when used alone or in combination with the anti-cancer chemotherapeu-
tic drug Cytosar but increased caspase-dependent PARP1 cleavage. In contrast 
with previous studies, we did not observe the negative effect of phosphatase 
activity inhibition and depletion on cells when a chemical inhibitor was used as 
monotherapy. Using a combination of GSK2830371 with Cytosar we were able 
to reduce the threshold of chemotherapy-dependent cytotoxicity and more ef-
ficiently eliminate leukemic cells. We propose considering inhibition of wild-
type p53-induced phosphatase as a prospective strategy in improving anti-AML 
therapy.
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Introduction
Acute myeloid leukemia (AML) is a frequent hematological malignancy that can 
develop spontaneously or be induced by chemotherapy or ionizing radiation. It is 
characterized by the clonal expansion of myeloid progenitors in the bone marrow 
and peripheral blood. AML has a multigenic nature with many genes involved 
in the pathogenesis of the disease, mainly genes involved in cell signaling, tran-
scriptional and epigenetic regulation (Cai and Levine, 2019). Many other my-
eloid proliferative or dysplastic pathologies with time may be transformed into 
AML. Currently, researchers and physicians count three steps in AML evolution 
from single mutations in progenitor cells in the bone marrow to fully developed 
leukemic cells with multiple mutations in various genes.
The first step when the hematopoietic progenitor acquires a mutation that 
gives it a competitive advantage in more rapid proliferation or resistance to stress 
is called Clonal Hematopoiesis of Indeterminate Potential, or CHIP. It is char-
acterized by the appearance and expansion of hematopoietic cells with certain 
mutations detected in at least 1% of blood cells. It can lead to changes in the 
functions of the gene and its products, but does not significantly affect the mor-
phology of cells and does not cause any pathological condition in the hemato-
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poietic system immediately, has indeterminate potential 
in contrast with the clonal detection of cells already as-
sociated with morphological changes (Myelodysplastic 
syndrome, MDS) or disease (Acute myeloid leukemia, 
AML). CHIP may predispose to the development of 
MDS, a condition with the appearance of atypical cells 
in the blood. Myelodysplastic syndrome includes several 
oncohematological conditions characterized by a defect 
in the maturation of cells in bone marrow, but usually at 
the beginning there are no other symptoms except atypi-
cal blood formula. In many cases, MDS cells acquire ad-
ditional mutations and transform into fully malignant 
leukemic cells, AML. 
Wild-type p53-induced phosphatase, WIP1, is one 
of the major regulators of DNA damage response and the 
p53 pathway that is frequently compromised in AML by 
mutations in the TP53 gene or the members of the DNA 
damage signaling pathway (Uyanik et al., 2017). Despite 
the recent addition of targeted therapy and the use of 
epigenetic drugs, the main drug of choice for AML treat-
ment remains cytarabine. Here we investigated the effect 
of WIP1 inhibition on AML cells’ sensitivity to cytara-
bine treatment.
Recently, Yu et al. showed that without any rela-
tion to mutation status in the fifth and sixth exons of 
the PPM1D gene (WIP1 protein), this gene was overex-
pressed in bone marrow cells of AML patients in com-
parison with control bone marrow cells from healthy 
donors (2020). Other researchers used RNA interference 
to deplete WIP1 in several AML cell lines. They showed 
that reducing WIP1 levels with siRNA to protein phos-
phatase, Mg2+/Mn2+ dependent 1D suppressed cell pro-
liferation and promoted cell apoptosis in AML-193 cells 
and KG-1 cells (Li et al., 2020).
Here we decided to analyze an approach more rel-
evant to clinical practice, by blocking WIP1 activity with 
a specific chemical inhibitor, GSK2830371. Moreover, 
we decided to test how WIP1  inhibition affects AML 
sensitivity to anti-cancer chemotherapy.
Material and methods
AML cell cultivation
Сells were obtained from the shared research facility “Ver-
tebrate cell culture collection” supported by the Ministry 
of Science and Higher Education of the Russian Federa-
tion (Agreement # 075-15-2021-683).
The OCI-AML-2 cell line (DSMZ no.: ACC 99) was 
cultured using 80–90 % alpha-MEM (with ribooxyribo-
nucleosides and deoxyribonucleosides) + 20 % h.i. FBS. 
The MONO-MAC-1 cell line (DSMZ ACC 252) was cul-
tured in 90 % RPMI 1640 + 10 % h.i. FBS + 2 mM L-glu-
tamine + 1x non-essential amino acids + 1 mM sodium 
pyruvate.
Сell viability assay
The CyQUANT™ XTT Cell Viability Assay kit was 
used to analyze viability. Cells at a concentration of 
1,000,000 per mL were seeded with the test compounds 
(GSK2830371  (GSK) (Selleckchem) and Cytosar (Cy-
tarabine) (Astellas Pharma Inc)) in a 96-well plate and 
cultured for 48 hours at 37 °C (5 % CO2). The readings 
were carried out according to the kit’s manual.
Western blotting
A polyacrylamide gel (10 %) was used for protein elec-
trophoresis according to the standard technique. A ni-
trocellulose membrane (Bio-Rad) with a pore diameter 
of 0.2 µM was used. The transfer of proteins from the 
gel to the membrane was carried out in a chamber (Bio-
Rad) at 0.3A for 2 hours. After blocking with 5 % milk 
in PBS-T (+ 0.1 % Tween-20), membranes were incu-
bated with specific antibodies (WIP1 F-10 (SantaCruz), 
PARP (Invitrogen), p-p38  MAPK (Cell Signaling), 
p-P53  (Ser15) (Cell Signaling)) overnight. After three 
washes with PBS-T (+ 0.1 % Tween-20), secondary an-
tibodies were applied accordingly and membranes were 
revealed with ECL reagents. 
Flow cytometry
CELL CYCLE
The cells were washed in PBS buffer, then fixed by the 
addition of cold ethanol to a final concentration of 50 % 
and subsequent incubation for 20  minutes at -20 °C. 
Cells were stained at 37 °C in PBS buffer containing 
RNase and propidium iodide. Stained cells were then 
analyzed on a CytoFLEX Beckman Counter in the PE 
channel.
APOPTOSIS
All of the procedures were performed according to kit 
instructions with Dead Cell Apoptosis Kit with Annexin 
V PE and SYTOX™ Green. Stained cells were then ana-
lyzed on a CytoFLEX Beckman Coulter in the APC and 
FITC channels.
Results
First, we performed data mining and found that muta-
tion frequency in the PPM1D gene is different in vari-
ous subsets of AML and AML-related diseases. The data 
presented in Table 1 indicate that despite a low general 
frequency of the PPM1D mutations in AML in general, 
about 1% of the cases, up to one-fifth of patients with a 
therapy-related AML or therapy-related pre-AML con-
dition, MDS, with a reported previous history of DNA 
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damaging agent treatment, had mutations in the regula-
tory domain of WIP1 phosphatase.
As discussed above, such mutations lead to the ex-
pression of a more stable and active enzyme in AML 
cells that may affect the leukemogenesis and leukemic 
cells’ responsiveness to the therapy. Therefore, we con-
cluded that WIP1 could play a role in the pathogenesis 
of AML, and the presence of mutations in the PPM1D 
gene could influence the choice of therapeutic strategy.
Our own Sanger sequencing of the PPM1D gene 
for more than 20 patient samples from the archives of 
the Institute of Oncology and Hematology, Almazov 
National Medical Research Centre, did not reveal any 
samples with mutations in PPM1D. The absence of mu-
tations may not only indicate the low frequency of mu-
tated PPM1D, but also can point to the necessity of using 
next generation sequencing with a reading depth of at 
least 500 copies to detect clones of AML cells with muta-
tions in the PPM1D gene.
In the next step, we decided to analyze WIP1 inhi-
bition effects on AML cells and changes in AML sensi-
tivity to anti-cancer chemotherapy.
For our studies, we selected two AML cell lines that 
are well-described in the literature: OCI-AML2  and 
Mono-Mac-1. According to French-British-American 
classification, they belong to FAB M4  (Acute myelo-
monocytic leukemia) and FAB M5  (Acute monocytic 
leukemia) classes of AML, correspondingly.
First, we analyzed how these two cell lines respond 
to the basic anti-AML chemotherapeutic drug Cytosar. 
Figure 1A shows that OCI-AML 2 cells are more sensi-
tive to the first-line treatment drug Cytosar, than Mo-
no-Mac-1 cells (Fig. 1A). Then we tested the toxicity of 
GSK2830371  (GSK), a highly specific WIP1  inhibitor, 
on those two AML cell lines in a biologically relevant 
range of concentrations from 0.1 uM to 5 uM. In con-
trast with previously published studies on the toxicity of 
WIP1 RNA interference in AML cells (Li et al., 2020), 
we did not observe the negative effect of WIP1 phospha-
tase activity inhibition on cell viability when a chemical 
inhibitor was used as monotherapy. At the same time, 
the combination of GSK2830371  with Cytosar signifi-
cantly potentiated the efficiency of chemotherapy in 
OCI-AML2  cells but not in Mono-Mac-1  cells, which 
are resistant to Cytosar (Fig. 1B).
As expected, treatment with Cytosar induced intra-
S-phase checkpoint and delayed cell cycle progression 
and proliferation of tumor cells (Fig. 1C). Cytarabine 
activates the major regulator of the intra-S-phase check-
point, ATR-Chk1 signaling. This signaling was reported 
as WIP1 phosphatase target previously (Lu et al., 2005; 
Mesa et al., 2005). GSK2830371 did not change the cell 
cycle profile either in control cells or in AML cells treat-
ed with Cytosar (Fig. 1C).
The caspase-dependent cleavage of PARP1 protein 
serves as a marker of apoptotic cell death. We observed 
the maximum intensity of cleaved product (89 kDa) in 
OCI-AML2 cells treated with a combination of WIP1 in-
hibitor and chemotherapeutic agent (Fig. 1D). In Mono-
Mac-1  cells, there was no obvious difference between 
cells treated only with Cytosar or with a combination 
of Cytosar and GSK2830371, but both samples had an 
extra band of 92 kDa that was not present in the control 
and in cells treated only with GSK. 
Another marker of apoptosis, the binding of An-
nexin V to the outer leaflet of the plasma membrane, was 
analyzed by flow cytometry. The results showed that, 






Healthy individuals 0.42 % Motomura et al., 2019
CHIP 4.6 % Genovese et al., 2014
Primary MDS 3 % Lindsley et al., 2017
De novo AML 1.2 % Kartal-Kaess et al., 2018
Therapy related MDS 15–20 % Hsu et al., 2018;  
Lindsley et al., 2017
Therapy related AML 19.5 % Hsu et al., 2018
Fig. 1. WIP1 inhibition sensitizes AML cells to chemotherapy
A — Influence of Cytosar (Cytarabine) on the viability of OCI-AML-2 and MONO-MAC-1 Cell lines.
Cell viability XTT assay was performed after 48 h of cultivation. The exponential concentration curve was built with Origin PRO (2019) 
software.
B — The effect of GSK2830371 (GSK) WIP1 inhibitor and chemotherapeutic drug Cytosar on AML cell viability. 
Two AML cell lines, OCI-AML-2 and MONO-MAC-1, were cultivated in the presence of GSK2830371 (GSK) and Cytosar for 48h before XTT 
assay.
— — no drug added; + — 1uM each of the compounds; ++ — 2uM each of the compounds; *- p<0.05 (n = 3).
C — The effect of GSK2830371 (GSK) and Cytosar on cell cycle
The cell cycle distribution of treated and non-treated OCI-AML-2 cells were analyzed using PI staining and FACS
D — PARP cleavage assay
The PARP cleavage by caspases was analyzed by Western blot with anti- PARP antibodies (Invitrogen).
E — The effect of GSK2830371 (GSK) and Cytosar on apoptosis
Flow cytometry dot plots for annexin V and CytotoxGreen staining of the two cell lines after 48 h of incubation with drugs
F — WIP1 signaling in AML cells after inhibition
Cells were treated with GSK2830371 (GSK) and Western blot was performed for WIP1, p-p38 MAPK and p-p53, and actin.
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similar to the viability assay, WIP1 inhibitor potentiated 
efficacy of Cytosar and increased the number of apoptot-
ic cells in treated OCI-AML2 cells. The same concentra-
tion of Cytosar induced cell death in Mono-Mac-1 cells 
to a lesser extent, and there was no difference between 
the treatment with Cytosar alone and the treatment with 
a combination of Cytosar and GSK2830371 (Fig. 1E). 
Finally, we checked WIP1  downstream signaling 
and verified the levels of WIP1  in both cell lines. We 
found that OCI-AML2 had high levels of WIP1 protein. 
In contrast, we were not able to detect the expression of 
the PPM1D gene in Mono-Mac1  AML cells with low-
affinity anti-WIP1 SCBT antibodies. As expected from 
the previous reports, GSK2830371  affected not only 
phosphatase activity but also reduced protein levels of 
WIP1  in OCI-AML2  cells (Fig. 1F). One of the main 
WIP1  targets, p38MAPK kinase was hyperphosphory-
lated on WIP1-targeted threonine 180  when dephos-
phorylation activity was inhibited by GSK2830371  in 
OCI-AML2  cells, but not in WIP1-deficient Mono-
Mac-1 AML cells. p53 transcriptional factor is another 
WIP1  target linked to apoptosis induction was de-
tected at very low levels in OCI-AML2  cells. The lev-
els of phosphorylated p53  at serine-15  were very high 
in Mono-Mac-1 AML cells but in this cell line, p53 was 
inactivated by mutations in the DNA binding domain 
(p.Arg273His). 
Discussion
In our study, monotherapy with WIP1  inhibitor 
GSK2830371  did not reduce the number of leukemic 
cells in comparison with the report published earlier 
this year, in which researchers used a different shRNA 
approach to deplete WIP1 in AML cells. WIP1 inhibi-
tion strategy in the treatment of AML was inefficient as 
monotherapy, but it shifted AML cells’ response to the 
widely used chemotherapeutic agent Cytosar towards 
apoptotic cell death. The difference in the response to 
WIP1  inhibitor treatment between the two AML cell 
lines we used in our study can be explained by differ-
ences in PPM1D expression. The undetectable levels 
of WIP1 in Mono-Mac-1 can be linked to the inactive 
mutant p53. In our previous work, we showed that tran-
scriptional factor p53 could bind to the promoter of the 
PPM1D gene and could activate its transcription (Rossi 
et al., 2008). The mutation in TP53 in Mono-Mac-1 cells 
is located in the DNA binding domain and severely 
compromised p53 functions as a transcriptional regula-
tor. P53 is a major tumor suppressor and a key protein 
in DNA damage response. P53  activation by a DNA-
damaging chemotherapeutic agent turns on apoptotic 
cell death. Therefore, the higher resistance of Mono-
Mac-1 cells to Cytosar can also be explained by inacti-
vating TP53 mutations in this cell line.
Increasing the efficiency of current protocols for the 
treatment of AML is one of the major tasks in oncohe-
matology. We conclude that WIP1 phosphatase could be 
a new target in the treatment of AML, and its inhibi-
tion potentiates the cytarabine efficiency in inducing cell 
death of AML cells by favoring apoptosis. At the same 
time, WIP1  levels in AML cells could be a prognostic 
marker determining the efficiency of the proposed anti-
tumor strategy.
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